



(19)


Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number : **0 640 596 A1**

(12)

EUROPEAN PATENT APPLICATION(21) Application number : **94306273.7**(51) Int. Cl.⁶ : **C07D 237/20, A61K 31/50**(22) Date of filing : **25.08.94**(30) Priority : **30.08.93 US 114251**(72) Inventor : Hunt, John T.
7 Skyfield Drive
Princeton, New Jersey (US)(43) Date of publication of application :
01.03.95 Bulletin 95/09(74) Representative : Thomas, Roger Tamlyn et al
D. Young & Co.
21 New Fetter Lane
London EC4A 1DA (GB)(84) Designated Contracting States :
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE**(71) Applicant : **BRISTOL-MYERS SQUIBB
COMPANY
P.O. Box 4000
Princeton, NJ 08543-4000 (US)**(54) **N-pyridazinyl-benzene (naphthalene-, biphenyl-) sulfonamide derivatives, their preparation and their use as endothelin antagonists.**

(57) Compounds of the formula



wherein :

R is phenyl, naphthyl or biphenyl, each of which may be substituted with R¹, R² and R³; R⁴, R⁵ and R¹² are each independently

- (a) hydrogen ;
- (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z¹, Z² and Z³ ;
- (c) halo ;
- (d) hydroxyl ;
- (e) cyano ;
- (f) nitro ;
- (g) -C(O)H or -C(O)R⁶ ;
- (h) -CO₂H or -CO₂R⁶ ;
- (i) -SH, -S(O)_nR⁶, -S(O)_m-OH, -S(O)_m-OR⁶, -O-S(O)_m-R⁶, -O-S(O)_mOH or -O-S(O)_m-OR⁶ ;
- (j) -Z⁴-NR⁷R⁸ ;
- (k) -Z⁴-N(R¹¹)-Z⁵-NR⁹R¹⁰ ; or
- (l) R⁴ and R⁵ or R⁵ and R¹² together are alkylene or alkenylene (either of which may be substituted with Z¹, Z² and Z³), completing a 4- to 8-membered saturated, unsaturated or aromatic ring together with the carbon atoms to which they are attached ;

provided that when R is phenyl, at least two of R⁴, R⁵ and R¹² are other than hydrogen ;

R¹, R², R³, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, Z¹, Z², Z³, Z⁴, Z⁵, n and m are as defined in the description ;

and pharmaceutically acceptable salts thereof are endothelin receptor antagonists useful, inter alia, as antihypertensive agents.

Field of the Invention

This invention relates to endothelin antagonists useful, *inter alia*, for treatment of hypertension.


5 Brief Description of the Invention

Compounds of the formula

10

I

15



and pharmaceutically acceptable salts thereof are endothelin receptor antagonists useful, *inter alia*, as anti-hypertensive agents. Throughout this specification, the above symbols are defined as follows:

R is phenyl, naphthyl or biphenyl, each of which may be substituted with R¹, R² and R³;

R¹, R² and R³ are each independently

- (a) hydrogen;
- (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z¹, Z² and Z³;
- (c) halo;
- (d) hydroxyl;
- (e) cyano;
- (f) nitro;
- (g) -C(O)H or -C(O)R⁶;
- (h) -CO₂H or -CO₂R⁶;
- (i) -SH, -S(O)_nR⁶, -S(O)_m-OH, -S(O)_m-OR⁶, -O-S(O)_m-R⁶, -O-S(O)_mOH or -O-S(O)_m-OR⁶;
- (j) -Z⁴-NR⁷R⁸; or
- (k) -Z⁴-N(R¹¹)-Z⁵-NR⁹R¹⁰;

35

R⁴, R⁵ and R¹² are each independently

- (a) hydrogen;
- (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z¹, Z² and Z³;
- (c) halo;

40

(d) hydroxyl;

(e) cyano;

(f) nitro;

(g) -C(O)H or -C(O)R⁶;

(h) -CO₂H or -CO₂R⁶;

45

(i) -SH, -S(O)_nR⁶, -S(O)_m-OH, S(O)_m-OR⁶, -O-S(O)_m-R⁶, -O-S(O)_mOH or -O-S(O)_m-OR⁶;

(j) -Z⁴-NR⁷R⁸;

(k) -Z⁴-N(R¹¹)-Z⁵-NR⁹R¹⁰; or

(l) R⁴ and R⁵, or R⁵ and R¹² together are alkylene or alkenylene (either of which may be substituted with Z¹, Z² and Z³), completing a 4- to 8-membered saturated, unsaturated or aromatic ring together with the carbon atoms to which they are attached;

provided that when R is phenyl, at least two of R⁴, R⁵ and R¹² are other than hydrogen;

R⁶ is alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any of which may be substituted with Z¹, Z² and Z³;

R⁷ is

50

(a) hydrogen;

(b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any of which may be substituted with Z¹, Z² and Z³;

(c) cyano;

(d) hydroxyl;
 (e) $-C(O)H$ or $-C(O)R^6$;
 (f) $-CO_2R^6$; or
 (g) $-SH$, $-S(O)_nR^6$, $-S(O)_m-OR^6$, $-O-S(O)_m-R^6$ or $-O-S(O)_m-OR^6$, except when Z^4 is $-S(O)_n-$;

5 R^8 is
 (a) hydrogen;
 (b) $-C(O)H$ or $-C(O)R^6$, except when Z^4 is $-C(O)-$ and R^7 is $-C(O)H$, $-C(O)R^6$ or $-CO_2R^6$; or
 (c) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any of which may be substituted with Z^1 , Z^2 and Z^3 ; or

10 R^7 and R^8 together are alkylene or alkenylene (either of which may be substituted with Z^1 , Z^2 and Z^3), completing a 3- to 8-membered saturated, unsaturated or aromatic ring together with the nitrogen atom to which they are attached;

15 R^9 is
 (a) hydrogen;
 (b) hydroxyl;
 (c) $-C(O)H$ or $-C(O)R^6$;
 (d) $-CO_2R^6$;
 (e) $-SH$, $-S(O)_nR^6$, $-S(O)_m-OR^6$, $-O-S(O)_m-R^6$ or $-O-S(O)_m-OR^6$; or
 (f) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl,
 20 any of which may be substituted with Z^1 , Z^2 and Z^3 ;

25 R^{10} is
 (a) hydrogen;
 (b) $-C(O)H$ or $-C(O)R^6$, except when Z^5 is $-C(O)-$ and R^9 is $-C(O)H$, $-C(O)R^6$ or $-CO_2R^6$; or
 (c) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl,
 30 any of which may be substituted with Z^1 , Z^2 and Z^3 ;

35 R^{11} is
 (a) hydrogen;
 (b) hydroxyl or $-CO_2R^6$, except when one of R^9 and R^{10} is hydroxyl or $-CO_2R^6$;
 (c) $-C(O)H$ or $-C(O)R^6$; or
 40 (d) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any of which may be substituted with Z^1 , Z^2 and Z^3 ;
 or any two of R^9 , R^{10} and R^{11} together are alkylene or alkenylene (either of which may be substituted with Z^1 , Z^2 and Z^3), completing a 3- to 8-membered saturated, unsaturated or aromatic ring together with the atoms to which they are attached;

45 Z^1 , Z^2 and Z^3 are each independently
 (a) hydrogen;
 (b) halo;
 (c) hydroxy;
 (d) alkyl, alkenyl, aralkyl, alkoxy, aryloxy or aralkoxy;
 (e) $-SH$, $-S(O)_nZ^6$, $-S(O)_m-OH$, $-S(O)_m-OZ^6$, $-O-S(O)_m-Z^6$, $-O-S(O)_m-OH$ or $-O-S(O)_m-OZ^6$;
 (f) oxo;
 (g) nitro;
 (h) cyano;
 (i) $-C(O)H$ or $-C(O)Z^6$;
 (j) $-CO_2H$ or $-CO_2Z^6$; or
 (k) $-Z^4-NZ^7Z^8$, $-Z^4-N(Z^{11})-Z^5Z^6$ or $-Z^4-N(Z^{11})-Z^5-NZ^7Z^8$;

50 Z^4 and Z^5 are each independently
 (a) a single bond;
 (b) $-Z^9-S(O)_m-Z^{10}$;
 (c) $-Z^9-C(O)-Z^{10}$;
 (d) $-Z^9-C(S)-Z^{10}$;
 (e) $-Z^9-O-Z^{10}$;
 (f) $-Z^9-S-Z^{10}$;
 (g) $-Z^9-O-C(O)-Z^{10}$; or
 55 (h) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any of which may be substituted with Z^1 , Z^2 and Z^3 ;

Z^6 , Z^7 and Z^8 are each independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, or aralkyl, or Z^7 and Z^8 together are alkylene or alkenylene, completing a 3-

to 8-membered saturated, unsaturated or aromatic ring together with the nitrogen atom to which they are attached;

Z^9 and Z^{10} are each independently a single bond, alkylene, alkenylene or alkynylene,
 Z^{11} is

5 (a) hydrogen;
(b) hydroxyl;
(c) $-C(O)H$, $-C(O)Z^6$ or $-CO_2Z^6$, provided that when Z^{11} is $-CO_2Z^6$, Z^6 is other than hydrogen; or
(d) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl;
or any two of Z^7 , Z^8 and Z^{11} together are alkylene or alkenylene, completing a 3- to 8- membered satu-

10 rated, unsaturated or aromatic ring together with the atoms to which they are attached;


m is 1 or 2; and
 n is 0, 1 or 2.

For compound I, when

R is

15

20



25

it is preferred that the sulfonamide is attached at position 1 or 2 and one of R^1 , R^2 and R^3 is attached at position 5 or 6;

one of R^1 , R^2 and R^3 is $-NR^7R^8$;
 R^4 , R^5 and R^{12} are independently hydrogen, alkyl or halo; and

30

R^7 and R^8 are each independently hydrogen, alkyl, or $-C(O)R^6$ wherein R^6 is alkyl.

Most preferred of these compounds are those wherein one of R^1 , R^2 and R^3 is $-NR^7R^8$ and the other two are hydrogen, $-NR^7R^8$ is attached at position 5 and the sulfonamide is attached at position 1, R^4 and R^5 are independently hydrogen or methyl, R^{12} is halo and R^7 and R^8 are hydrogen, methyl, methylethyl, or acetyl.

35

For compound 1, when R is biphenyl, it is preferred that one of R^1 , R^2 and R^3 is 4'-alkyl or 4'-branched alkyl.

Detailed Description of the Invention

Listed below are definitions of terms used in this specification. These definitions apply to the terms as used throughout this specification, individually or as part of another group, unless otherwise limited in specific instances.

The terms "alkyl" and "alkoxy" refer to straight or branched chain hydrocarbon groups having 1 to 10 carbon atoms. The terms "lower alkyl" and "lower alkoxy" refer to groups of 1 to 4 carbon atoms, which are preferred.

The term "aryl" or "ar-" refers to phenyl, naphthyl, and biphenyl.

45

The term "alkenyl" refers to straight or branched chain hydrocarbon groups of 2 to 10 carbon atoms having at least one double bond. Groups of two to four carbon atoms are preferred.

The term "alkynyl" refers to straight or branched chain groups of 2 to 10 carbon atoms having at least one triple bond. Groups of two to four carbon atoms are preferred.

50

The term "alkylene" refers to a straight chain bridge of 1 to 5 carbon atoms connected by single bonds (e.g., $-(CH_2)_m-$ wherein m is 1 to 5), which may be substituted with 1 to 3 lower alkyl groups.

The term "alkenylene" refers to a straight chain bridge of 2 to 5 carbon atoms having one or two double bonds that is connected by single bonds (e.g., $-CH=CH_2-CH=CH-$, $-CH_2-CH=CH-$, $-CH_2-CH=CH-CH_2-$, $-C(CH_3)_2CH=CH-$ and $-CH(C_2H_5)-CH=CH-$) which may be substituted with 1 to 3 lower alkyl groups.

55

The term "alkynylene" refers to a straight chain bridge of 2 to 5 carbon atoms that has a triple bond therein, is connected by single bonds, and may be substituted with 1 to 3 lower alkyl groups. Exemplary alkynylene groups are $-C\equiv C-$, $-CH_2-C\equiv C-$, $-CH(CH_3)-C\equiv C-$ and $-C\equiv C-CH(C_2H_5)CH_2-$.

The term "alkanoyl" refers to groups of the formula $-C(O)alkyl$.

The terms "cycloalkyl" and "cycloalkenyl" refers to cyclic hydrocarbon groups of 3 to 8 carbon atoms.

The term "aralkyl" refers to an alkyl group substituted by one or more aryl groups.

The terms "halogen" and "halo" refers to fluorine, chlorine, bromine and iodine.

The compounds of formula I form salts which are also within the scope of this invention. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful, e.g., in isolating or purifying the compounds of this invention.

The compounds of formula I may form salts with alkali metals such as sodium, potassium and lithium, with alkaline earth metals such as calcium and magnesium, with organic bases such as dicyclohexylamine, benzathine, N-methyl-D-glucamide and hydrabamine and with amino acids such as arginine, lysine and the like. Such salts may be obtained by reacting compound I with the desired ion in a medium in which the salt precipitates or in an aqueous medium followed by lyophilization.

When the R¹ to R⁵ or R¹² substituents comprise a basic moiety, such as amino or substituted amino, compound I may form salts with a variety of organic and inorganic acids. Such salts include those formed with hydrochloric acid, hydrogen bromide, methanesulfonic acid, sulfuric acid, acetic acid, maleic acid, benzenesulfonate, toluenesulfonate and various other sulfonates, nitrates, phosphates, borates, acetates, tartrates, malates, citrates, succinates, benzoates, ascorbates, salicylates and the like. Such salts may be formed by reacting compound I in an equivalent amount of the acid in a medium in which the salt precipitates or in an aqueous medium followed by lyophilization.

In addition, when the R¹ to R⁵ or R¹² substituents comprise a basic moiety such as amino, zwitterions ("inner salts") may be formed.

Certain of the R¹ to R⁵ and R¹² substituents of compound I may contain asymmetric carbon atoms. Such compounds of formula I may exist, therefore, in enantiomeric and diasteromeric forms and in racemic mixtures thereof. All are within the scope of this invention.

The compounds of formula I are antagonists of ET-1, ET-2, and/or ET-3 and are useful in treatment of conditions associated with increased ET levels (e.g., dialysis, trauma and surgery) and of all endothelin-dependent disorders. They are thus useful as antihypertensive agents. By the administration of a composition having one (or a combination) of the compounds of this invention, the blood pressure of a hypertensive mammalian (e.g., human) host is reduced. They are also useful in pregnancy - induced hypertension and coma (preeclampsia and eclampsia), acute portal hypertension and hypertension secondary to treatment with erythropoietin.

The compounds of the present invention are also useful in the treatment of disorders related to renal, glomerular and mesangial cell function, including acute and chronic renal failure, glomerular injury, renal damage secondary to old age or related to dialysis, nephrosclerosis (especially hypertensive nephrosclerosis), nephrotoxicity (including nephrotoxicity related to imaging and contrast agents and to cyclosporine), renal ischemia, primary vesicoureteral reflux, glomerulosclerosis, and the like. The compounds of this invention may also be useful in the treatment of disorders related to paracrine and endocrine function.

The compounds of the present invention are also useful in the treatment of endotoxemia or endotoxin shock as well as hemorrhagic shock.

The compounds of the present invention are also useful in hypoxic and ischemic disease and as anti-ischemic agents for the treatment of, for example, cardiac, renal and cerebral ischemia and reperfusion (such as that occurring following cardiopulmonary bypass surgery), coronary and cerebral vasospasm, and the like.

In addition, the compounds of this invention may also be useful as anti-arrhythmic agents; anti-anginal agents; anti-fibrillatory agents; anti-asthmatic agents; anti-atherosclerotic and anti-arteriosclerotic agents; additives to cardioplegic solutions for cardiopulmonary bypasses; adjuncts to thrombolytic therapy; and anti-diarrheal agents. The compounds of this invention may also be useful in therapy for myocardial infarction; therapy for peripheral vascular disease (e.g., Raynaud's disease and Takayasu's disease); treatment of cardiac hypertrophy (e.g., hypertrophic cardiomyopathy); treatment of primary pulmonary hypertension (e.g., plexogenic, embolic) in adults and in the newborn and pulmonary hypertension secondary to heart failure, radiation and chemotherapeutic injury, or other trauma; treatment of central nervous system vascular disorders such as stroke, migraine, and subarachnoid hemorrhage; treatment of central nervous system behavioral disorders; treatment of gastrointestinal diseases such as ulcerative colitis, Crohn's disease, gastric mucosal damage, ulcer and ischemic bowel disease; treatment of gall bladder or bile duct-based diseases such as cholangitis; treatment of pancreatitis; regulation of cell growth and cell migration; treatment of benign prostatic hyperplasia and hypertrophy; treatment of lipid disorders; treatment of restenosis following angioplasty or following any procedures including transplantation; therapy for congestive heart failure including inhibition of fibrosis; inhibition of left ventricular dilatation, remodeling and dysfunction; and treatment of hepatotoxicity and sudden death.

The compounds of this invention may be useful in the treatment of sickle cell disease including the initiation and/or evolution of the pain crises of this disease; treatment of the deleterious consequences of ET-producing tumors such as hypertension resulting from hemangiopericytoma; treatment of early and advanced liver disease and injury including attendant complications (e.g., hepatotoxicity, fibrosis and cirrhosis); treatment of

spastic diseases of the urinary tract and/or bladder; treatment of hepatorenal syndrome; treatment of immunological diseases involving vasculitis such as lupus, systemic sclerosis, mixed cryoglobulinemia; and treatment of fibrosis associated with renal dysfunction and hepatotoxicity. The compounds of this invention may be useful in therapy for metabolic and neurological disorders; cancer; insulin-dependent and non insulin-dependent diabetes mellitus; neuropathy; retinopathy; maternal respiratory distress syndrome; dysmenorrhea; epilepsy, hemorrhagic and ischemic stroke; bone remodeling; and chronic inflammatory diseases such as rheumatoid arthritis, osteoarthritis, sarcoidosis and eczematous dermatitis (all types of dermatitis).

The compounds of this invention can also be formulated in combination with endothelin converting enzyme (ECE) inhibitors, such as phosphoramidon; thromboxane receptor antagonists; potassium channel openers; thrombin inhibitors (e.g., hirudin and the like); growth factor inhibitors such as modulators of PDGF activity; platelet activating factor (PAF) antagonists; angiotensin II (AII) receptor antagonists; renin inhibitors; angiotensin converting enzyme (ACE) inhibitors such as captopril, zofenopril, fosinopril, ceranapril, alacepril, enalapril, delapril, pentopril, quinapril, ramipril, lisinopril, and salts of such compounds; neutral endopeptidase (NEP) inhibitors; calcium channel blockers; potassium channel activators; beta-adrenergic agents; antiarrhythmic agents; diuretics, such as chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide or benzothiazide as well as ethacrynic acid, tricrynahen, chlorthalidone, furosemide, musolimine, bumetanide, triamterene, amiloride and spironolactone and salts of such compounds; thrombolytic agents such as tissue plasminogen activator (tPA), recombinant tPA, streptokinase, urokinase, prourokinase, and anisoylated plasminogen streptokinase activator complex (APSAC, Eminase, Beecham Laboratories). If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent within its approved dosage range. The compounds of this invention may also be formulated with or useful in conjunction with antifungal and immunosuppressive agents such as amphotericin B, cyclosporins and the like to counteract the glomerular contraction and nephrotoxicity secondary to such compounds. The compounds of this invention may also be used in conjunction with hemodialysis.

The compounds of the invention can be administered orally or parenterally to various mammalian species known to be subject to such maladies, e.g., humans, in an effective amount within the dosage range of about 0.1 to about 100 mg/kg, preferably about 0.2 to about 50 mg/kg and more preferably about 0.5 to about 25 mg/kg (or from about 1 to about 2500 mg, preferably from about 5 to about 2000 mg) in single or 2 to 4 divided daily doses.

The active substance can be utilized in a composition such as tablet, capsule, solution or suspension containing about 5 to about 500 mg per unit of dosage of a compound or mixture of compounds of formula I or in topical form for wound healing (0.01 to 5% by weight compound of formula I, 1 to 5 treatments per day). They may be compounded in conventional matter with a physiologically acceptable vehicle or carrier, excipient, binder, preservative, stabilizer, flavor, etc., or with a topical carrier such as Plastibase (mineral oil gelled with polyethylene) as called for by accepted pharmaceutical practice.

The compounds of the invention may also be administered topically to treat peripheral vascular diseases and as such may be formulated as a cream or ointment.

The compounds of formula I can also be formulated in compositions such as sterile solutions or suspensions for parenteral administration. About 0.1 to 500 milligrams of a compound of formula I is compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, etc., in a unit dosage form as called for by accepted pharmaceutical practice. The amount of active substance in these compositions or preparations is such that a suitable dosage in the range indicated is obtained.


The compounds of the present invention may be prepared as follows.
45 A sulfonamide



is coupled with

50

III



55


in an anhydrous organic solvent in the presence of a base (e.g., Cs2CO3) to form compound I.

The sulfonamide II may be prepared from R-SO₂halo and NH₃.

Alternatively, the sulfonamide II wherein R is biphenyl substituted with R¹, R² and R³ may be prepared by metal (e.g., palladium (0)) catalyzed coupling of the associated halo compound

5

10



with aryl metalloids (i.e., aryl derivatives of tin, silicon, boron and the like, such as phenylboronic acid). A phenylboronic acid may be prepared by treating an aryl halide with n-butyl lithium or magnesium turnings in an anhydrous organic solvent (e.g., tetrahydrofuran) and adding trimethylborate and finally aqueous hydrochloric acid.

For compounds wherein any of R¹ to R⁵ or R¹² comprise reactive functionalities, the reactants may be treated with protecting agents prior to coupling. Suitable protecting agents and procedures for use thereof are generally known in the art. Exemplary protecting groups are benzyl, halocarbobenzoyloxy, tosyl and the like for hydroxyl; and carbobenzoyloxy, halocarbobenzoyloxy, acetyl, benzoyl and the like for amino. Such groups may then be removed from the resulting protected analogue of compound I by treatment with one or more deprotecting agents. Suitable deprotecting agents and procedures for use thereof are generally known in the art.

Similarly, the nitrogen atom of the sulfonamide core may need to be protected during preparation of compound I. Suitable protecting groups are also generally known in the art. The protecting group may be added by treating the free amine with the halide of the protecting group at about 0°C in the presence of a base (e.g., triethylamine). The protecting group may be removed by treatment with an acid (e.g., trifluoroacetic acid) in an organic solvent (e.g., methylene chloride) at about 0°C.

The invention will now be further described by the following working examples, which are preferred embodiments of the invention. These examples are meant to be illustrative rather than limiting.


30

Example 1

N-(6-Chloro-3-pyridazinyl)-5-(dimethylamino)-1-naphthalenesulfonamide

35

40



A solution of dansylamide (0.50 g, 2.00 mmol), 3,6-dichloropyridazine (0.37 g, 2.50 mmol) and cesium carbonate (1.33 g, 4.10 mmol) in dimethylformamide (2 mL) was heated at 105°C for 6 hours, allowed to cool, and poured into water. The solution was acidified to pH 3 and the resulting brown solid was filtered and washed with water. The solid was dissolved in half saturated aqueous sodium bicarbonate. The solution was acidified to pH 3 and the resulting brown solid was filtered, washed with water and dissolved in 10% isopropanol/methylene chloride. The solution was washed with brine, dried (magnesium sulfate) and evaporated. The residue was chromatographed on silica with 2%, then 3% methanol/methylene chloride to afford 0.29 g of product containing a small amount of dansylamide. The solid was dissolved in half saturated aqueous sodium bicarbonate and the solution was filtered. The filtrate was acidified to pH 3 with solid potassium hydrogen sulfate and extracted with methylene chloride. The organic solution was dried (magnesium sulfate) and evaporated to afford 0.24 g (33%) of Example 1 as a bright yellow solid. Melting point: 92-100°C.

55

Analysis calculated for C₁₆H₁₅N₄O₂SCl-0.41 H₂O-0.15 C₄H₁₀O.

5


Calc'd:	C, 52.29;	H, 4.58;	N, 14.69;	S, 8.40;	Cl, 9.30.
Found:	C, 52.29;	H, 4.34;	N, 14.53;	S, 8.32;	Cl, 9.38.

Example 2

10

N-(6-Chloro-5-methyl-3-pyridazinyl)-5-(dimethylamino)-1-naphthalenesulfonamide

15



20

A solution of dansylamide (1.5 g, 6.0 mmol), 3,6-dichloro-4-methylpyridazine (0.98 g, 6.0 mmol) and cesium carbonate (4.1 g, 12.6 mmol) in dimethylformamide (8 mL) was heated at 105°C for 8 hours, allowed to cool, and poured into half-saturated sodium hydrogen carbonate (300 mL). A large amount of a black gummy solid was filtered from the solution, and the filtrate was acidified with solid potassium hydrogen sulfate and extracted with methylene chloride (3x). The combined organic phases were dried (magnesium sulfate), evaporated and warmed under high vacuum to afford 1.03 g of black gum. Flash chromatography on silica (30%, then 50% ethyl acetate/hexanes) afforded 0.17 g of crude faster moving isomer (FMI; TLC, 50% ethyl acetate/hexanes, R_f=0.60) as a pink solid and 0.19 g of nearly clean slower moving isomer (SMI; TLC, 50% ethyl acetate/hexanes, R_f = 0.43) as a grey green gum. The SMI material was recrystallized from ethyl acetate/hexanes to afford 93 mg (4%) of Example 2 as an off white solid. Melting point: 112-115°C.

25

30

Analysis calculated for C₁₇H₁₇N₄O₂SCl-0.07 H₂O.

35


Calc'd:	C, 53.99;	H, 4.57;	N, 14.81;	S, 8.48;	Cl, 9.37.
Found:	C, 53.99;	H, 4.36;	N, 14.84;	S, 8.36;	Cl, 9.35.

40

Example 3**N-(6-Chloro-4-methyl-3-pyridazinyl)-5-(dimethylamino)-1-naphthalenesulfonamide**

45

50



The FMI material from Example 2 was suspended in 5% aqueous sodium hydrogen carbonate, methanol was added, and the solution was warmed until nearly complete dissolution took place. The solution was evaporated to remove only the methanol and the resulting heterogeneous solution was filtered of insoluble dansylamide. The filtrate was acidified with solid potassium hydrogen sulfate and extracted with ethyl acetate. The organic phase was dried (magnesium sulfate) and evaporated to afford 130 mg of pink solid, which was dis-

solved in a small amount of warm ethyl acetate. Hexane was added and the product was allowed to crystallize. The crystalline solid was filtered, rinsed with ethyl acetate/hexanes and dried to afford 96 mg (4%) of Example 3 as a yellow solid. Melting point: 192-194°C.

5

Analysis calculated for C ₁₇ H ₁₇ N ₄ O ₂ SCl.					
Calc'd:	C, 54.18;	H, 4.55;	N, 14.87;	S, 8.51;	Cl, 9.41.
Found:	C, 54.25;	H, 4.56;	N, 14.69;	S, 8.22;	Cl, 9.40.


10

Example 4

N-(6-Chloro-3-pyridazinyl) [1,1'-biphenyl]-2-yl- sulfonamide

15

20



25

A. [1,1'-biphenyl]-2-yl-sulfonamide

To a degassed solution of 2-bromo-benzenesulfonamide (0.7 g, 3.0 mmole) and tetrakis(triphenylphosphine) palladium (0) (0.21 g, 0.18 mmole) in benzene (25 mL) was added 2M aqueous sodium carbonate (15 mL) followed by a solution of phenylboronic acid (0.44 g, 3.6 mmole) in 95% aqueous ethanol. The two phase solution was refluxed for 18 hours, cooled to room temperature and diluted with water. The mixture was extracted twice with ethyl acetate and the combined organic phases were washed with brine, dried (magnesium sulfate) filtered and evaporated. The residue was chromatographed (silica gel, 2:1 hexanes:ethyl acetate) to afford 0.25 g (36%) of compound A as a yellow solid.

30

B. N-(6-Chloro-3-pyridazinyl)[1,1'-biphenyl]-2-yl- sulfonamide

To a solution of compound A (0.30 g, 1.3 mmol) and 3,6-dichloropyridazine (0.21 g, 1.4 mmol) in dry dimethylformamide (4 mL) was added cesium carbonate (0.46 g, 1.4 mmol). The mixture was heated at 105°C for 24 hours, cooled to room temperature, diluted with water (40 mL) and acidified to pH 4 with 6N aqueous hydrochloric acid. The resulting tan precipitate was collected by filtration, rinsed with water and dissolved in ethyl acetate. The solution was extracted 3 times with 2N aqueous sodium carbonate (3 x 50 mL) and the combined extracts were acidified to pH 4 with 6N aqueous hydrochloric acid. The resulting tan precipitate was collected by filtration, rinsed with water, and dried under vacuum to afford 0.24 g (54%) of Example 4 as a tan solid, m.p. 176-181°C.

40


45

50

Analysis calculated for C ₁₆ H ₁₂ N ₃ O ₂ SCl-1.11 H ₂ O.					
Calc'd:	C, 52.53;	H, 3.92;	N, 11.49;	S, 8.76;	Cl, 9.68.
Found:	C, 52.78;	H, 3.69;	N, 11.24;	S, 8.70;	Cl, 9.39.

Example 5

N-(6-Chloro-3-pyridazinyl)-4'-(2-methylpropyl)[1,1'-biphenyl]-2-sulfonamide



15 **A. 4-(2-methylpropyl)-benzeneboronic acid**

To a suspension of 0.68 g (28.15 mmol) of magnesium turnings in 50 mL of tetrahydrofuran under argon, a crystal of iodine was added and a solution of 4-bromo-isobutylbenzene (6.0 g, 28.15 mmol) in 25 mL of tetrahydrofuran was added at such a rate that a gentle reflux was maintained. The mixture was refluxed for an additional hour, cooled to room temperature and added in portions over 15 minutes to a solution of trimethylborate (2.93 g, 28.15 mmol) in 50 mL of ether at -78°C under argon. After 30 minutes at -78°C, the solution was warmed to room temperature, stirred for 90 minutes and 10% aqueous hydrochloric acid (100 mL) was added. After 10 minutes, the solution was extracted with ether (3 x 100 mL) and the combined ether extracts were extracted with 1 M sodium hydroxide (3 x 100 mL). The aqueous extracts were acidified with dilute hydrochloric acid to pH 2 and extracted with ether (3 x 100 mL). The combined ether extracts were washed once with water (100 mL), dried and evaporated to afford 3.5 g of a white solid. Crystallization from ether/hexanes provided 2.3 g (46%) of compound A as a white solid in two crops, m.p. 134-135°C.

30 **B. N-(1,1-dimethylethyl)-4'-(2-methylpropyl)-1,1'-biphenyl-2-sulfonamide**

To a solution of N-(1,1-dimethylethyl)-2-bromobenzenesulfonamide (500 mg, 1.71 mmol) in toluene (14 mL), sodium carbonate (363 mg, 3.42 mmol) in water (7 mL) and compound A (366 mg, 2.05 mmol) in ethanol (7 mL) (all solvents argon-degassed) was added tetrakis(triphenylphosphine)palladium (0) (119 mg, 0.103 mmol). The yellow mixture was heated at reflux for 1 hour, cooled to room temperature and poured into half-saturated sodium bicarbonate (30 mL). The mixture was extracted with ethyl acetate (2 x 50 mL) and the combined organic layers were dried (magnesium sulfate) and evaporated. Chromatography (silica, 10% ethyl acetate/hexanes) afforded compound B as a white solid (503 mg, 85%).

40 **C. 4'-(2-methylpropyl)-1,1'-biphenyl-2-sulfonamide**

A solution of compound B (503 mg, 1.45 mmol) in cold trifluoroacetic acid (5 mL) was stirred for 5 hours as it warmed to room temperature. The solvent was evaporated and the residue was passed through a silica plug with ethyl acetate. The eluate was evaporated to provide compound C as an oil (306 mg, 100%).

45 **D. N-(6-Chloro-3-pyridazinyl)-4'-(2-methylpropyl)[1,1'-biphenyl]-2-sulfonamide**

To a solution of compound C (300 mg, 1.73 mmol) and 3,6-dichloropyridazine (350 mg, 2.34 mmol) in dry dimethylformamide (4 mL) was added cesium carbonate (770 mg, 2.34 mmol). The mixture was heated at 100°C for 3 hours, cooled to room temperature, diluted with water (75 mL) and acidified to pH 3 with 6N aqueous hydrochloric acid. The mixture was extracted with ethyl acetate (3 x 50 mL) and the combined organic phases were washed with water and brine, and dried (magnesium sulfate). The residue was chromatographed on silica gel using 2:3 ethyl acetate/hexanes to afford 200 mg (29 %) of Example 5 as a tan solid, mp 108-110°C.

5

Analysis for C₂₀H₂₀N₃O₂SCI-0.15 H₂O.

Calc'd:	C, 59.37;	H, 5.05;	N, 10.38;	S, 7.92;	Cl, 8.76.
Found:	C, 59.37;	H, 4.99;	N, 10.03;	S, 7.94;	Cl, 9.09.


5

Claims

10

1. A compound of the formula

15



20

or such a compound in pharmaceutically acceptable salt form, wherein:

R is phenyl, naphthyl or biphenyl, each of which may be substituted with R¹, R² and R³;
R¹, R² and R³ are each independently

25

- (a) hydrogen;
- (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z¹, Z² and Z³;
- (c) halo;
- (d) hydroxyl;
- (e) cyano;
- (f) nitro;
- (g) -C(O)H or -C(O)R⁶;
- (h) -CO₂H or -CO₂R⁶;
- (i) -SH, -S(O)_nR⁶, -S(O)_m-OH, -S(O)_m-OR⁶, O-S(O)_m-R⁶ -O-S(O)_mOH or -O-S(O)_m-OR⁶;
- (j) -Z⁴-NR⁷R⁸; or
- (k) -Z⁴-N(R¹¹)-Z⁵-NR⁹R¹⁰;

35

R⁴, R⁵ and R¹² are each independently

40

- (a) hydrogen;
- (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z¹, Z² and Z³;

45

- (c) halo;
- (d) hydroxyl;
- (e) cyano;
- (f) nitro;
- (g) -C(O)H or -C(O)R⁶;
- (h) -CO₂H or -CO₂R⁶;
- (i) -SH, -S(O)_nR⁶, -S(O)_m-OH, -S(O)_m-OR⁶, -O-S(O)_m-R⁶, -O-S(O)_mOH or -O-S(O)_m-OR⁶;
- (j) -Z⁴-NR⁷R⁸;
- (k) -Z⁴-N(R¹¹)-Z⁵-NR⁹R¹⁰; or

50

- (l) R⁴ and R⁵, or R⁵ and R¹² together are alkylene or alkenylene (either of which may be substituted with Z¹, Z² and Z³), completing a 4- to 8-membered saturated, unsaturated or aromatic ring together with the carbon atoms to which they are attached;

provided that when R is phenyl, at least two of R⁴, R⁵ and R¹² are other than hydrogen;

55

R⁶ is alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any of which may be substituted with Z¹, Z² and Z³;

R⁷ is

- (a) hydrogen;
- (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aral-

kyl, any of which may be substituted with Z¹, Z² and Z³;

- (c) cyano;
- (d) hydroxyl;
- (e) -C(O)H or -C(O)R⁶;
- (f) -CO₂R⁶; or

5 (g) -SH, -S(O)_nR⁶, -S(O)_m-OR⁶, -O-S(O)_m-R⁶ or -O-S(O)_m-OR⁶, except when Z⁴ is -S(O)_n-; R⁸ is

- (a) hydrogen;
- (b) -C(O)H or -C(O)R⁶, except when Z⁴ is -C(O)- and R⁷ is -C(O)H, -C(O)R⁶ or -CO₂R⁶; or

10 (c) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any of which may be substituted with Z¹, Z² and Z³; or

R⁷ and R⁸ together are alkylene or alkenylene (either of which may be substituted with Z¹, Z² and Z³), completing a 3- to 8- membered saturated, unsaturated or aromatic ring together with the nitrogen atom to which they are attached;

15 R⁹ is

- (a) hydrogen;
- (b) hydroxyl;
- (c) -C(O)H or -C(O)R⁶;
- (d) -CO₂R⁶;

20 (e) -SH, -S(O)_nR⁶, -S(O)_m-OR⁶, -O-S(O)_m-R⁶ or -O-S(O)_m-OR⁶; or

- (f) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any of which may be substituted with Z¹, Z² and Z³;

R¹⁰ is

- (a) hydrogen;
- (b) -C(O)H or -C(O)R⁶, except when Z⁵ is -C(O)- and R⁹ is -C(O)H, -C(O)R⁶ or -CO₂R⁶; or
- (c) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any of which may be substituted with Z¹, Z² and Z³;

R¹¹ is

- (a) hydrogen;
- (b) hydroxyl or -CO₂R⁶, except when one of R⁹ and R¹⁰ is hydroxyl or -CO₂R⁶;
- (c) -C(O)H or -C(O)R⁶; or
- (d) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any of which may be substituted with Z¹, Z² and Z³;

35 or any two of R⁹, R¹⁰ and R¹¹ together are alkylene or alkenylene (either of which may be substituted with Z¹, Z² and Z³), completing a 3- to 8-membered saturated, unsaturated or aromatic ring together with the atoms to which they are attached;

Z¹, Z² and Z³ are each independently

- (a) hydrogen;
- (b) halo;
- (c) hydroxy;
- (d) alkyl, alkenyl, aralkyl, alkoxy, aryloxy or aralkoxy;
- (e) -SH, -S(O)_nZ⁶, -S(O)_m-OH, -S(O)_m-OZ⁶, -O-S(O)_m-Z⁶, -O-S(O)_mOH or -O-S(O)_m-OZ⁶;
- (f) oxo;
- (g) nitro;
- (h) cyano;
- (i) -C(O)H or -C(O)Z⁶;
- (j) -CO₂H or -CO₂Z⁶; or
- (k) -Z⁴-NZ⁷Z⁸, Z⁴-N(Z¹¹)-Z⁵Z⁶ or -Z⁴-N(Z¹¹)-Z⁵-NZ⁷Z⁸;

45 Z⁴ and Z⁵ are each independently

- (a) a single bond;
- (b) -Z⁹-S(O)_m-Z¹⁰;
- (c) -Z⁹-C(O)-Z¹⁰;
- (d) -Z⁹-C(S)-Z¹⁰;
- (e) -Z⁹-O-Z¹⁰;
- (f) -Z⁹-S-Z¹⁰;
- (g) -Z⁹-O-C(O)-Z¹⁰; or
- (h) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any of which may be substituted with Z¹, Z² and Z³;

Z^6 , Z^7 and Z^8 are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, or aralkyl, or Z^7 and Z^8 together are alkylene or alkenylene, completing a 3- to 8-membered saturated, unsaturated or aromatic ring together with the nitrogen atom to which they are attached;

5 Z^9 and Z^{10} are each independently a single bond, alkylene, alkenylene or alkynylene, Z^{11} is

- (a) hydrogen;
- (b) hydroxyl;
- (c) $-C(O)H$, $-C(O)Z^6$ or $-CO_2Z^6$, provided that when Z^{11} is $-CO_2Z^6$, Z^6 is other than hydrogen; or
- 10 (d) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl;


or any two of Z^7 , Z^8 and Z^{11} together are alkylene or alkenylene, completing a 3- to 8- membered saturated, unsaturated or aromatic ring together with the atoms to which they are attached;

m is 1 or 2; and

15 n is 0, 1 or 2.

2. A compound of the formula

20



25

or such a compound in pharmaceutically acceptable salt form, wherein:

R is naphthyl or biphenyl, each of which may be substituted with R^1 , R^2 and R^3 ;

30 R^1 , R^2 and R^3 are each independently

- (a) hydrogen;
- (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z^1 , Z^2 and Z^3 ;
- (c) halo;
- (d) hydroxyl;
- (e) cyano;
- (f) nitro;
- (g) $-C(O)H$ or $-C(O)R^6$;
- (h) $-CO_2H$ or $-CO_2R^6$;
- (i) $-SH$, $-S(O)_nR^6$, $-S(O)_m-OH$, $-S(O)_m-OR^6$, $-O-S(O)_m-R^6$, $-O-S(O)_m-OH$ or $-O-S(O)_m-OR^6$;
- 40 (j) $-Z^4-NR^7R^8$; or
- (k) $-Z^4-N(R^{11})-Z^5-NR^9R^{10}$;

R^4 , R^5 and R^{12} are each independently

- (a) hydrogen;
- (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aryloxy, aralkyl or aralkoxy, any of which may be substituted with Z^1 , Z^2 and Z^3 ;
- (c) halo;
- (d) hydroxyl;
- (e) cyano;
- (f) nitro;
- (g) $-C(O)H$ or $-C(O)R^6$;
- (h) $-CO_2H$ or $-CO_2R^6$;
- (i) $-SH$, $-S(O)_nR^6$, $S(O)_m-OH$, $-S(O)_m-OR^6$, $-O-S(O)_m-R^6$, $-O-S(O)_m-OH$ or $-O-S(O)_m-OR^6$;
- (j) $-Z^4-NR^7R^8$;
- 50 (k) $-Z^4-N(R^{11})-Z^5-NR^9R^{10}$; or
- (l) R^4 and R^5 , or R^5 and R^{12} together are alkylene or alkenylene (either of which may be substituted with Z^1 , Z^2 and Z^3), completing a 4- to 8-membered saturated, unsaturated or aromatic ring together with the carbon atoms to which they are attached;

R^6 is alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any of which may be substituted with Z^1 , Z^2 and Z^3 ;

R^7 is

- (a) hydrogen;
- (b) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any of which may be substituted with Z^1 , Z^2 and Z^3 ;
- (c) cyano;
- (d) hydroxyl;
- (e) $-C(O)H$ or $-C(O)R^6$;
- (f) $-CO_2R^6$; or
- (g) $-SH$, $-S(O)_nR^6$, $-S(O)_m-OR^6$, $-O-S(O)_m-R^6$ or $-O-S(O)_m-OR^6$, except when Z^4 is $-S(O)_n-$;

R^8 is

- (a) hydrogen;
- (b) $-C(O)H$ or $-C(O)R^6$, except when Z^4 is $-C(O)-$ and R^7 is $-C(O)H$, $-C(O)R^6$ or $-CO_2R^6$; or
- (c) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any of which may be substituted with Z^1 , Z^2 and Z^3 ; or

R^7 and R^8 together are alkylene or alkenylene (either of which may be substituted with Z^1 , Z^2 and Z^3), completing a 3- to 8-membered saturated, unsaturated or aromatic ring together with the nitrogen atom to which they are attached;

R^9 is

- (a) hydrogen;
- (b) hydroxyl;
- (c) $-C(O)H$ or $-C(O)R^6$;
- (d) $-CO_2R^6$;
- (e) $-SH$, $-S(O)_nR^6$, $-S(O)_m-OR^6$, $-O-S(O)_m-R^6$ or $-O-S(O)_m-OR^6$; or
- (f) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any of which may be substituted with Z^1 , Z^2 and Z^3 ;

R^{10} is

- (a) hydrogen;
- (b) $-C(O)H$ or $-C(O)R^6$, except when Z^5 is $-C(O)-$ and R^9 is $-C(O)H$, $-C(O)R^6$ or $-CO_2R^6$; or
- (c) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any of which may be substituted with Z^1 , Z^2 and Z^3 ;

R^{11} is

- (a) hydrogen;
- (b) hydroxyl or $-CO_2R^6$, except when one of R^9 and R^{10} is hydroxyl or $-CO_2R^6$;
- (c) $-C(O)H$ or $-C(O)R^6$; or
- (d) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any of which may be substituted with Z^1 , Z^2 and Z^3 ;

or any two of R^9 , R^{10} and R^{11} together are alkylene or alkenylene (either of which may be substituted with Z^1 , Z^2 and Z^3), completing a 3- to 8-membered saturated, unsaturated or aromatic ring together with the atoms to which they are attached;

Z^1 , Z^2 and Z^3 are each independently

- (a) hydrogen;
- (b) halo;
- (c) hydroxy;
- (d) alkyl, alkenyl, aralkyl, alkoxy, aryloxy or aralkoxy;
- (e) $-SH$, $-S(O)_nZ^6$, $-S(O)_m-OH$, $-S(O)_m-OZ^6$, $-O-S(O)_m-Z^6$, $-O-S(O)_m-OH$ or $-O-S(O)_m-OZ^6$;
- (f) oxo;
- (g) nitro;
- (h) cyano;
- (i) $-C(O)H$ or $-C(O)Z^6$;
- (j) $-CO_2H$ or $-CO_2Z^6$; or
- (k) $-Z^4-NZ^7Z^8$ $Z^4-N(Z^{11})-Z^5Z^6$ or $-Z^4-N(Z^{11})-Z^5-NZ^7Z^8$;

Z^4 and Z^5 are each independently

- (a) a single bond;
- (b) $-Z^9-S(O)_m-Z^{10}$;
- (c) $-Z^9-C(O)-Z^{10}$;
- (d) $-Z^9-C(S)-Z^{10}$;

(e) -Z⁹-O-Z¹⁰;
 (f) -Z⁹-S-Z¹⁰;
 (g) -Z⁹-O-C(O)-Z¹⁰; or
 (h) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl, any of which may be substituted with Z¹, Z² and Z³;

Z⁶, Z⁷ and Z⁸ are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, or aralkyl, or Z⁷ and Z⁸ together are alkylene or alkenylene, completing a 3- to 8-membered saturated, unsaturated or aromatic ring together with the nitrogen atom to which they are attached;

Z⁹ and Z¹⁰ are each independently a single bond, alkylene, alkenylene or alkynylene, Z¹¹ is


(a) hydrogen;
 (b) hydroxyl;
 (c) -C(O)H, -C(O)Z⁶ or -CO₂Z⁶, provided that when Z¹¹ is -CO₂Z⁶, Z⁶ is other than hydrogen; or
 (d) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl or aralkyl;

or any two of Z⁷, Z⁸ and Z¹¹ together are alkylene or alkenylene, completing a 3- to 8- membered saturated, unsaturated or aromatic ring together with the atoms to which they are attached;

m is 1 or 2; and

n is 0, 1 or 2.

3. The compound of Claim 1, wherein R is



with the sulfonamide attached at position 1 or 2 and one of R¹, R² and R³ attached at position 5 or 6.


4. The compound of Claim 3, wherein one of R¹, R² and R³ is -NR⁷R⁸.

5. The compound of Claim 4, wherein R⁷ and R⁸ are each independently hydrogen, alkyl or C(O)alkyl.

6. The compound of Claim 5, wherein R⁷ and R⁸ are each independently hydrogen, methyl, methylethyl or acetyl.

7. The compound of Claim 3, wherein R⁴, R⁵ and R¹² are independently hydrogen, alkyl or halo.

8. The compound of Claim 1, having the formula



9. The compound of Claim 8, wherein R⁷ and R⁸ are each independently hydrogen, alkyl or C(O)alkyl.

10. The compound of Claim 9, wherein R⁷ and R⁸ are each independently hydrogen, methyl, methylethyl or

acetyl.

11. The compound of Claim 1, wherein R is biphenyl which may be substituted with R¹, R² and R³.
- 5 12. The compound of Claim 11, wherein one of R¹, R² and R³ is 4'-alkyl or 4'-branched alkyl.
13. The compound of Claim 12, wherein one of R¹, R² and R³ is 4'-alkyl.
14. The compound of Claim 12, wherein one of R¹, R² and R³ is 4'-branched alkyl.
- 10 15. The compound of Claim 1, which is:
N-(6-Chloro-3-pyridazinyl)-5-(dimethylamino)-1-naphthalenesulfonamide;
N-(6-Chloro-5-methyl-3-pyridazinyl)-5-(dimethylamino)-1 -naphthalenesulfonamide;
N-(6-Chloro-4-methyl-3-pyridazinyl)-5-(dimethylamino)-1-naphthalenesulfonamide;
N-(6-Chloro-3-pyridazinyl)[1,1'-biphenyl]-2-yl-sulfonamide; or
15 N-(6-Chloro-3-pyridazinyl)-4'-(2-methylpropyl)[1,1'-biphenyl]-2-sulfonamide.
16. Use of a compound of any one of Claims 1-15 for the manufacture of a medicament for the treatment of endothelin- related disorders in a mammal.
- 20 17. Use of a compound of any one of Claims 1-15 for the manufacture of a medicament for the treatment of hyper-tension.
18. Use of a compound of any one of Claims 1-15 for the manufacture of a medicament for the treatment of renal, glomerular or mesangial cell disorders.
- 25 19. Use of a compound of any one of Claims 1-15 for the manufacture of a medicament for the treatment of endotoxemia.
20. Use of a compound of any one of Claims 1-15 for the manufacture of a medicament for the treatment of ischemia.

30

35

40

45

50

55



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 94 30 6273

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	EP-A-0 510 526 (F. HOFFMANN-LA ROCHE & CO. AG) 28 October 1992 * the whole document * ---	1-20	C07D237/20 A61K31/50
Y	EP-A-0 526 708 (F. HOFFMANN-LA ROCHE AG) 10 February 1993 * the whole document * ---	1-20	
P, Y	NATURE (LONDON) vol. 365 , 21 October 1993 pages 759 - 761 CLOZEL M ET AL. 'Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist' * the whole document * ---	1-20	
P, Y	JOURNAL OF MEDICINAL CHEMISTRY vol. 37, no. 3 , 4 February 1994 pages 329 - 331 STEIN P.D. ET AL. 'The discovery of sulfonamide endothelin antagonists and the development of the orally active ET(A) antagonist 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide' * page 330; tables 1,2 * ---	1-20	
P, Y	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS vol. 201, no. 1 , 30 May 1994 pages 228 - 234 CHAN M.F. ET AL. 'Identification of a new class of ET(A) selective endothelin antagonists by pharmacophore directed screening' * compound 3 * * page 230; table 1 * * scheme 1 * * page 232 * ---	1-20	
-/-			
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
MUNICH	18 October 1994	Hartrampf, G	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone	Y : particularly relevant if combined with another document of the same category		
A : technological background	O : non-written disclosure		
P : intermediate document			



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 94 30 6273

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
P, Y	EP-A-0 558 258 (E.R. SQUIBB & SONS, INC.) 1 September 1993 * the whole document * ---	1-20	
P, Y	EP-A-0 569 193 (E.R. SQUIBB & SONS, INC.) 10 November 1993 * the whole document * ---	1-20	
A	PROGRESS IN MEDICINAL CHEMISTRY (ELLIS G.P. & WEST G.B. EDS.), ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM vol. 27 , 1990 pages 2 - 49 HEINISCH G. & FRANK H. 'Pharmacologically active pyridazine derivatives. Part 1' * page 25 - page 27 * ---	1-20	
A	ARZNEIMITTEL-FORSCHUNG vol. 15, no. 11 , November 1965 pages 1309 - 1317 KRÜGER-THIEMER E. ET AL. 'Die antibakterielle Wirkung des nicht eiweißgebundenen Anteils der Sulfanilamide im menschlichen Plasmawasser' * the whole document * ---	1-20	TECHNICAL FIELDS SEARCHED (Int.Cl.6)
A	JOURNAL OF MEDICINAL CHEMISTRY vol. 35, no. 9 , 1 May 1992 pages 1493 - 1508 DOHERTY A.M. 'Endothelin: A new challenge' * the whole document * -----	1-20	
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
MUNICH	18 October 1994	Hartrampf, G	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone	Y : particularly relevant if combined with another document of the same category		
A : technological background	O : non-written disclosure		
P : intermediate document			